Kidney360 · 2026
Dapagliflozin Reduces Kidney Inflammation in Alport Syndrome by Inhibiting the Stimulator of IFN Genes Pathway in Renal Tubular Epithelial Cells.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zheng Qimin, Zhao Yafei, Jin Yuanmeng, Yu Shuwen, Liu Yunzi, Yu Hanlan, Fang Zhengying, Yang Li, Weng Qinjie, Xu Jing, Pan Xiaoxia, Gu Xiangchen, Xie Jingyuan
Аннотация
KEY POINTS: Dapagliflozin reduces proteinuria in patients with Alport syndrome. Dapagliflozin plays an anti-inflammatory role by inhibiting the stimulator of IFN genes pathway in tubular epithelial cells of Alport syndrome mice.
BACKGROUND: Alport syndrome (AS) is a hereditary kidney disease caused by COL4A3/4/5 mutations that lack of effective treatments. Sodium-glucose cotransporter 2 inhibitors have demonstrated renal and cardiovascular protective effects in patients with CKD; however, their long-term effects in patients with AS and the underlying mechanisms remain to be clarified.
METHODS: We conducted a single-arm, prospective study to examine the effect of dapagliflozin in patients with AS. In parallel, Col4a3 p.C1615Y-mutant mice (129S2/Sv background) were used as an AS model to investigate the renoprotective mechanisms of dapagliflozin.
RESULTS: A total of twenty-one patients with AS were enrolled. After approximately 12 months of follow-up (12.6±1.2 months), the mean 24-hour urinary protein decreased by 29% to 1.25±0.73 g from baseline (1.75±0.90; P < 0.001). The eGFR showed no significant difference compared with baseline (76±28 versus 77±29 ml/min per 1.73 m 2 , P = 0.57). In the animal studies, dapagliflozin significantly reduced macrophage infiltration and the expression of inflammatory cytokines levels in the renal cortex of Col4a3 -mutant mice. Mechanistic studies showed that stimulator of IFN genes (STING) pathway was activated in the renal cortex and tubular epithelial cells (TECs) from Col4a3 mice, contributing to a proinflammatory phenotype. Dapagliflozin effectively inhibited STING activation and suppressed inflammatory cytokines production in mutant TECs.
CONCLUSIONS: Dapagliflozin can reduce proteinuria in patients with AS and plays an anti-inflammatory role by inhibiting the STING pathway in TECs of AS mice.
BACKGROUND: Alport syndrome (AS) is a hereditary kidney disease caused by COL4A3/4/5 mutations that lack of effective treatments. Sodium-glucose cotransporter 2 inhibitors have demonstrated renal and cardiovascular protective effects in patients with CKD; however, their long-term effects in patients with AS and the underlying mechanisms remain to be clarified.
METHODS: We conducted a single-arm, prospective study to examine the effect of dapagliflozin in patients with AS. In parallel, Col4a3 p.C1615Y-mutant mice (129S2/Sv background) were used as an AS model to investigate the renoprotective mechanisms of dapagliflozin.
RESULTS: A total of twenty-one patients with AS were enrolled. After approximately 12 months of follow-up (12.6±1.2 months), the mean 24-hour urinary protein decreased by 29% to 1.25±0.73 g from baseline (1.75±0.90; P < 0.001). The eGFR showed no significant difference compared with baseline (76±28 versus 77±29 ml/min per 1.73 m 2 , P = 0.57). In the animal studies, dapagliflozin significantly reduced macrophage infiltration and the expression of inflammatory cytokines levels in the renal cortex of Col4a3 -mutant mice. Mechanistic studies showed that stimulator of IFN genes (STING) pathway was activated in the renal cortex and tubular epithelial cells (TECs) from Col4a3 mice, contributing to a proinflammatory phenotype. Dapagliflozin effectively inhibited STING activation and suppressed inflammatory cytokines production in mutant TECs.
CONCLUSIONS: Dapagliflozin can reduce proteinuria in patients with AS and plays an anti-inflammatory role by inhibiting the STING pathway in TECs of AS mice.